A strategy for inducing preferential proliferation of the engrafted hepatocytes over host liver cells should markedly increase the benefit of hepatocyte transplantation for the treatment of liver diseases and ex vivo gene therapy. We hypothesized that preparative hepatic irradiation (HIR) to inhibit host hepatocellular regeneration in combination with the mitotic stimulus of host hepatocellular apoptosis should permit repopulation of the liver by transplanted cells. To test this hypothesis, congeneic normal rat hepatocytes were transplanted into UDP-glucuronosyltransferase (UGT1A1)-deficient jaundiced Gunn rats (a model of Crigler-Najjar syndrome type I), following HIR and adenovirus-mediated FasL gene transfer. Progressive repopulation of the liver by engrafted UGT1A1-proficient hepatocytes over 5 months was demonstrated by the appearance of UGT1A1 protein and enzyme activity in the liver, biliary bilirubin glucuronides secretion, and long-term normalization of serum bilirubin levels. This is the first demonstration of massive hepatic repopulation by transplanted cells by HIR and FasL-induced controlled apoptosis of host liver cells.
Introduction
Hepatocyte transplantation (HT) is being evaluated for the treatment of patients with liver failure and inherited liver diseases, [1] [2] [3] and for ex vivo gene therapy. 4, 5 The ability to cryopreserve isolated hepatocytes for immediate availability and to transplant cells from a single donor to multiple recipients makes this modality attractive. Additionally, HT is metabolically less stressful than liver transplantation. The normal host liver architecture provides a scaffold for the transplanted cells to integrate into the host liver, providing considerable restorative potential. Thus, for the treatment of inherited metabolic diseases, missing gene products can be substituted by transplanting normal primary hepatocytes from allogeneic donors. Alternatively, to obviate the need for immunosuppression, hepatocytes isolated from a resected liver lobe can be transduced with a therapeutic gene and then transplanted back to the donor for ex vivo gene therapy. This simple approach holds promise for inherited metabolic disorders, such as Crigler-Najjar syndrome type I, ornithine transcarbamylase deficiency and hemophilia.
However, because the number of hepatocytes that can be transplanted safely at one time is limited, complete correction of metabolic diseases has not been possible by HT 2 or hepatocyte-based ex vivo gene therapy. 4 Providing selective growth advantage to transplanted hepatocytes could markedly enhance the efficacy of HT. Therefore, we and others are investigating strategies for massively repopulating the host liver by preferential mitotic stimulation of the engrafted hepatocytes. Primary hepatocytes transplanted into the normal liver exhibit infrequent mitosis, which is characteristic of quiescent hepatocytes. A significant increase in the proportion of the transplanted cells over the host hepatocytes requires the combination of a strong mitotic stimulus to the engrafted cells and a failure of proliferation of the host hepatocytes. Proof of this principle has been obtained in recipient genetically modified mice in which the host hepatocytes undergo spontaneous cell death. These models include transgenic mice that express urokinasetype plasminogen activator (uPA) in the liver, 6 and mice with disruption of the fumarylacetoacetate hydrolase (FAH) gene. 7 Although these elegant studies have demonstrated the ability of adult hepatocytes to undergo massive proliferation, these methods are not directly applicable to inherited disorders that do not cause excessive loss of the host hepatocytes. Other investigators have used an activating Fas antibody to induce apoptosis in host liver cells, followed by the transplantation of hepatocytes from Bcl-2 transgenic mice, that were protected against the activating antibody. 8 To develop a more generally applicable system, normal rat hepatocytes were transplanted into Nagase analbuminemic rats that were subjected to partial hepatectomy (PH) and treated with retrorsine to inhibit host hepatocyte proliferation. This resulted in significant correction of the albumin deficiency. 9 Since retrorsine is carcinogenic, we have investigated the possibility of hepatic irradiation (HIR) as a preparative method for hepatic repopulation by transplanted non-irradiated hepatocytes. 10 We demonstrated that a regimen of whole liver irradiation and 68% PH, followed by transplantation of normal unirradiated cells, resulted in massive repopulation by the transplanted hepatocytes in the host liver. 11 To extend our observations into potential clinical application of HIR as a preparative regimen for HT, we are seeking an alternative to PH.
Fas antigen (CD95/APO-1), a member of tumor necrosis factor (TNF) and nerve growth factor receptor superfamily, is a type I transmembrane protein expressed in a variety of tissues. 12, 13 The liver expresses Fas constitutively. 14, 15 The primary function of Fas is to trigger apoptosis in susceptible target cells when bound either to the natural Fas ligand (FasL) 16 or to anti-Fas agonistic antibodies.
14 FasL is a type II transmembrane protein belonging to the TNF family, expressed primarily in activated cytotoxic lymphocytes and natural killer cells. 16, 17 The Fas receptor/FasL system plays an important role in B-and T-lymphocyte development and maturation 16 and is a powerful tool for the removal of undesired target cells, such as virally infected or malignant cells. 18 In this work, we examined whether proliferative stimuli other than PH could achieve extensive hepatocyte repopulation and whether Fas-mediated apoptosis could serve as a non-surgical alternative to PH. 
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We hypothesized that a preparative regimen of HIR would suppress host hepatocellular regeneration in response to induction of hepatocellular apoptosis after transient expression of FasL in hepatocytes following infection with a FasL-expressing adenoviral vector (AxCALNFasL). The FasL-expressing adenoviral vectors were used as a convenient experimental tool to induce Fas-activated hepatocellular apoptosis. The effect of preparative HIR and controlled FasL expression on HT was evaluated in Gunn rats that lack hepatic uridinediphosphoglucuronate glucuronosyltransferase (UGT1A1) activity toward bilirubin. Gunn rats do not excrete bilirubin glucuronides in bile and, consequently, accumulate unconjugated bilirubin in plasma. Gunn rat is a model of Crigler-Najjar syndrome type I. UGT1A1-proficient, congeneic normal Wistar-RHA rats were used as hepatocyte donors. The advantage of using the Gunn rat model is that the function of the engrafted normal hepatocytes can be evaluated by the determination of serum bilirubin levels, excretion of bilirubin glucuronides in bile and UGT1A1 activity in liver biopsy specimens. 19 
Results
We generated a recombinant adenovirus capable of transferring the coding region of FasL separated from the promoter by a Lox-P-flanked DNA segment (AxCALNFasL). 20 FasL is expressed upon excision of a LoxP-flanked sequence by another adenoviral vector expressing Cre recombinase (AxCANCre) (Figure 1 ). This system was required because the adenovirus generating 293 cells express Fas constitutively and are killed upon expression of FasL. 20, 21 In our experiments, the desired level of Fas ligand expression was obtained by adjusting the dose of the Cre-recombinase-expressing vector, AxCANCre. Pilot experiments were performed to determine the optimum dose of AxCALNCre. AxCALNFasL was injected into the tail vein of Gunn rats that had undergone HIR at a constant dose of 5 Â 10 9 pfu, along with AxCALNCre, at doses varying from 1 Â 10 7 to 10 Â 10 7 pfu. Serum alanine aminotransferase (ALT) levels were measured and recipient rats were observed for survival. All rats receiving the highest doses of AxCALNCre (1 Â 10 8 pfu) died within 15-48 h of virus Irradiation and FasL expression for hepatic repopulation M Takahashi et al injection. However, AxCANCre at 5 Â 10 7 pfu was not associated with mortality, although significant elevations of serum ALT levels were observed. These results were consistent with a strong threshold effect of the dose of recombinant adenoviruses. For subsequent experiments, we used AxCANCre at 5 Â 10 7 pfu. Hepatic FasL protein content was examined by immunotransblot after intravenous administration of 5 Â 10 9 pfu of AxCALNFasL and 5 Â 10 7 pfu of AxCANCre using a rabbit polyclonal anti-FasL antibody. FasL expressed from the transgene was detectable within 6 h of injection of the recombinant adenoviruses and was maintained for 24 h (Figure 1c ). The FasL bands were not detectable when the antibody was preabsorbed with the peptide, that had been used to raise the antibody, demonstrating the specificity of the immunoreactive band (not shown). Twenty-four hours after the injection of AxCALNFasL+AxCANCre, 60710% of hepatocytes Figure  2d ). HE staining did not demonstrate any pathomorphological changes in the brain, lungs, heart, intestine and kidneys. In these extrahepatic tissues, TUNELpositive cells were not increased, compared to untreated control (o1% in the heart, the kidneys and the brain, o10% in the intestinal and the alveolar epithelium). Death of hepatocytes after FasL expression was also indicated by the elevation of serum alanine transaminase (ALT) levels. Eighteen hours after the injection of AxCALNFasL+AxCANCre, in rats receiving HIR, ALT levels increased to 10137622 IU/ml. The increase of serum ALT concentration was probably contributed by the death of the FasL-expressing cells, as well as killing of the neighboring hepatocytes, as suggested by the appearance of clusters of dying hepatocytes in HEstained liver sections. The ALT levels declined to 3387239 IU/ml by 48 h after virus administration. The rapid decline of serum ALT and the marked reduction of the FasL content 48 h after the injection of the recombinant adenoviruses may be explained by the apoptosis and disappearance of the transgene-expressing hepatocytes. As the FasL content of the liver was very low at 48 h, we chose this time point to transplant congeneic hepatocytes, so that the engrafted cells would not be affected by the overexpression of FasL.
DNA synthesis by proliferative hepatocytes was examined using BrdU incorporation. As expected, in the livers of control untreated rats, few if any hepatocyte stained positive for BrdU incorporation (Figure 3a) . Two days after injection of AxCALNFasL+AxCANCre in nonirradiated rats, many cells were BrdU-positive ( Figure  3b ). In contrast, in rats that recieved hepatic (50 Gy) along with the injection of the recombinant virus pair, very few hepatocytes were BrdU-positive (Figure 3c ). These findings indicated that FasL-mediated apoptosis of the hepatocytes provided a strong mitotic stimulus 48 h after gene transfer (the time of HT), but the irradiated host hepatocytes were unable to proliferate in response to that stimulus.
Serum bilirubin levels were observed up to 150 days after HT (Figure 4a ). One day after AxCALNFasL+Ax-CANCre injection, serum bilirubin levels increased Irradiation and FasL expression for hepatic repopulation M Takahashi et al transiently, reflecting hepatocyte apoptosis. Rats receiving HIR only showed minor elevation of the serum bilirubin concentrations. Congeneic normal hepatocytes were transplanted into the Gunn rats 2 days after the preparative treatment. In the group that received HIR and AxCALNFasL+AxCANCre injection, serum bilirubin levels declined progressively to normal levels (0.970.4 mg/ml) over 48 days (Po0.001) and remained normal throughout the duration of observation (150 days). In the FasL only and irradiation only groups, there was only a minor reduction of serum bilirubin levels. Serum ALT levels increased after the injection of AxCALNFasL+AxCANCre because of the apoptosis of host hepatocytes (Figure 4b ). The ALT levels returned to baseline within a week and remained normal throughout the 6 months of our experiments (5575.0 IU/ml).
Excretion of conjugated bilirubin in bile was evaluated by high pressure liquid chromatographic analysis of pigments excreted in bile. At the termination of the experiments, polyethylene cannulae were placed in the bile duct of the rats for the collection of bile. The control Gunn rat bile contained no bilirubin glucuronide peaks (Figure 5a ). In contrast, 150 days after HT into Gunn rats pretreated with HIR and FasL expression, prominent bilirubin diglucuronide and monoglucuronide peaks were seen (Figure 5b) . Together, bilirubin glucuronides constituted over 95% of total bilirubin excreted in bile.
Western blot analysis for hepatic UGT1A1 content was performed using a rat-UGT1A1-specific anti-peptide antibody. The normal 52 kDa rat UGT1A1 band was seen in normal Wistar rat liver, but was missing in the liver of control, untreated Gunn rats (Figure 6a ). In rats receiving HT after HIR and FasL expression, UGT1A1 concentrations increased to 20-60% of normal Wistar rat in the various lobes of the liver, except in the caudate lobe in which UGT1A1 expression was minimal ( Figure  6b) . Notably, the caudate lobe is shielded during our irradiation protocol. With FasL expression or HIR alone as a preparative regimen, there was a minimal expression of UGT1A1 (Fig 6a) .
UGT1A1 activity in the liver homogenates was assayed in vitro using bilirubin as a substrate. The enzyme activity was undetectable in untreated Gunn rats. In the AxCALNFasL+AxCANCre+irradiation group, the enzyme activity in the various lobes varied from 25% to 60% of normal rat liver UGT1A1 activity, with the exception of the caudate lobe which did not exhibit the enzyme activity. In the group that received AxCALNFasL+AxCANCre but no irradiation, and the group that received irradiation only, UGT1A1 activities in the liver lobes ranged from undetectable to 5% of normal.
Repopulation of the liver was also examined by immunohistochemical staining for rat UGT1A1 Figure 7 ). Liver sections from control, untreated Gunn rats were negative for the immunohistochemical staining. In Gunn rats treated with FasL+HIR, significant repopulation was seen 150 days after transplantation of normal hepatocytes. UGT1A1-positive donor hepatocytes were seen in clusters in all zones of the liver, indicating proliferation of the engrafted cells. The extent of repopulation ranged from 20% to 60% in various lobes. It varied from lobe to lobe and in different parts of the same lobe, from region to region. The highest degree Figure 7 Immunohistochemistry of the liver for rat UGT1A1. Immunohistochemical staining was performed using a rat UGT1A1-specific antibody as described in the text. The left panels shows the liver of untreated control Gunn rat. The right panel shows the liver (left lobe) of a Gunn rat 150 days after transplantation of normal hepatocytes from a congeneic donor, after preparative irradiation and FasL expression. (Figure 6b) . Interestingly, the repopulated areas containing the clusters of donor hepatocytes showed normal liver architecture, as shown by HE staining (data not shown). No evidence of radiation-induced liver injury or neoplastic transformation was noted. The liver cells were distributed in single-cell thick cords that were separated by normal hepatic sinusoids. Hepatocytes, bile duct epithelia, endothelial cells and other non-parenchymal cells exhibited normal morphology. To address directly the functionality of the repopulating hepatocytes, we assayed serum albumin and transferrin levels. Compared to untreated controls (3.570.2 g/dl), the serum albumin levels in animals treated with HIR+FasL+HT were 3.270.2 g/dl. The serum transferrin levels in the experimental group were 22.574.0 mg/dl, and were not significantly different from that of the control animals (31.076.9 mg/dl). At the completion of experiments, the serum aspartate transaminase (AST), ALT and gammaglutamyl transpeptidase (GGT) levels were normal and serum alphafetoprotein levels were undetectable in these animals.
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Discussion
Taken together, our results show that FasL-induced apoptosis provided a strong mitotic stimulus to hepatocytes, while HIR suppressed host hepatocyte proliferation. This combination provided a selective proliferative advantage to transplanted non-irradiated hepatocytes, which progressively repopulated the host liver. The lobeto-lobe variation in the proportion of UGT1A1-positive hepatocytes and the UGT1A1 content probably reflects the difference in the absorbed irradiation dose in the various liver lobes. The lower level of repopulation of the posterior liver lobes could be because of a relatively lower exposure to the irradiation, resulting from the attenuation of the X-rays by the overlying anterior liver lobes. The caudate lobe, which was shielded from the irradiation in our protocol, exhibited little repopulation by the donor hepatocytes.
Our study provides a proof of the principle that Fasmediated hepatocellular apoptosis can be used as a noninvasive alternative to PH, 11 which, in combination with HIR, permits massive hepatic repopulation by engrafted hepatocytes. The FasL-expressing adenoviral vector system was used as a convenient experimental tool to induce Fas-activated hepatocellular apoptosis. We expect that other approaches to induce Fas-mediated apoptosis, for example, the administration of anti-Fas agonistic antibodies, should produce similar effects. The agonistic antibody (Jo-mab) has been employed to augment hepatic repopulation. 8, 22, 23 In these studies, engrafted bcl-2-expressing donor hepatocytes were protected from Jo-mab-induced apoptosis and resulted in up to 15-20% repopulation of the host liver by repeated injections of an agonistic anti-Fas antibody. Although the bcl-2-protection approach is scientifically interesting, constant expression of bcl-2 from an integrated gene would be associated with long-term cancer risk. In our preparative irradiation approach, primary hepatocytes could be transplanted without the need for genetic manipulation, and a single episode of Fas-mediated apoptosis was sufficient to achieve a much greater degree (52715%) of repopulation. Although on the basis of RT-PCR studies, FasL has been reported to be expressed in the liver nonspecifically after administration of recombinant adenoviruses, 24 it is unclear whether the expression is in hepatocytes or activated lymphocytes present in the liver tissue. In our study, administration of AxCALNFasL without AxCANCre resulted in only mild ALT elevation and no histological evidence of increased apoptosis of hepatocytes. This confirmed that the FasL expression and the consequent hepatocellular apoptosis after administration of the two recombinant viruses together were controlled by the dose of AxCANCre. Safety of this controlled FasL expression system was shown by the lack of mortality or long-term morbidity in the experimental group, when appropriate doses of the AxCALNFasL/AxCANCre combination was injected. Since adenoviral gene transfer in rodents is predominantly hepatocyte-preferred and the Fas receptor is expressed in a limited number of tissue, 25 no significant extrahepatic pathomorphological changes occurred after AxCALNFasL/AxCANCre administration. Histomorphological analysis at the end of the study showed no residual liver damage from the combination of FasL expression and HIR. This was consistent with our previous report demonstrating that HT prevented the delayed histomorphological and functional manifestations of radiation-induced liver injury in a rat model. 26 An added degree of safety may have been provided by the caudate lobe of the liver, which was not exposed to irradiation in our protocol. The differentiated phenotype and physiological function of the repopulating hepatocytes were demonstrated by the complete normalization of serum bilirubin levels in Gunn rats and maintenance of normal levels of serum albumin, transferrin, AST, ALT and GGT.
In humans, preparative irradiation is used as a standard regimen for bone marrow transplantation. 27, 28 The novelty of our work is in the application of HIR for repopulation of transplanted hepatocytes. HIR has been used for a long time for the treatment of liver cancer. In the older studies, the doses required to eradicate liver cancer were associated with radiation-induced liver damage (RILD), precluding its wide application. 29 However, the newer techniques of three-dimensional conformal HIR have enabled investigators to deliver higher doses to parts of the liver, without inducing RILD. 30, 31 Radiation sensitivity of the liver varies in different species. The rat liver is less sensitive to radiation-induced liver injury than is human liver, as evidenced by our finding that 50 Gy doses in single fractions were tolerated by the Gunn rats, whereas doses exceeding 30-35 Gy are known to cause long-term radiation injury to the human liver. 29, 32 Therefore, it is expected that the repopulation of human liver will require a lower radiation dose. Furthermore, in humans, conformal irradiation should permit precisely targeted, controlled Irradiation and FasL expression for hepatic repopulation M Takahashi et al delayed ablation of the host hepatocytes within specific liver lobes. The level of repopulation achieved by this method was sufficient to normalize completely the serum bilirubin levels in Gunn rats. It should be noted that for clinical applications, complete correction of the metabolic abnormality is not usually needed. For example, in patients with Crigler-Najjar syndrome type I, long-term reduction of serum bilirubin levels to 30-50% of pretreatment concentrations (which would be still 10-15 times above normal) should be sufficient to provide safety from bilirubin encephalopathy. Therefore, even a lower level of repopulation may be sufficient for potential application of this approach in the treatment of many inherited metabolic diseases. In summary, we have described a novel preparative regimen for massive repopulation of the host liver by transplanted hepatocytes. These experiments will form the basis of strategies for repopulating the liver starting with small number of normal hepatocytes for the treatment of acquired and inherited liver diseases.
Materials and methods

Animals
Inbred Gunn rats and normal Wistar-RHA rats (congeneic to the Gunn rats) were obtained from our colony at the special core of the Marion Bessin Liver Research Center of the Albert Einstein Collage of Medicine. The animals were housed in the Institute for Animal Studies at the Albert Einstein College of Medicine under 14 h light/10 h dark cycles, and provided with pelleted chow and water ad libitum. Male UGT1A1-deficient homozygous Gunn rats weighing 200-250 g were used as transplant recipients for these studies. Congeneic normal Wistar-RHA rats were used as hepatocyte donors. The experimental protocols were approved by the Institutional Animal Care and Use Committee.
Isolation of primary hepatocytes
Normal donor hepatocytes were harvested by collagenase perfusion of the livers of Wistar-RHA rats as previously described. 33 Hepatocyte viability was determined by trypan blue exclusion, and cells with 485% viability were used for transplantation.
Irradiation of Gunn rat liver
Irradiation was performed as previously described. 26 Briefly, the abdomen was opened by mid-line incision, and two 3 Â 4 cm lead shields (2 mm thick) were wedged beneath the liver and overlying the stomach, intestines and spleen without compressing the hepatic artery, aorta and portal vein. All hepatic lobes, except the caudate lobe were irradiated using a Philips orthovoltage unit operating at 320 kVP, 10 mA, and 0.5 mm copper filtration. The liver was exposed to a single dose of 50 Gy at 320 cGy/min.
Adenoviral vector system expressing rat FasL
We generated an adenoviral system to express conditionally rat FasL in the host hepatocytes for induction of apoptosis. 20 This system consisted of two recombinant adenoviruses, one expressing rat FasL (AxCALNFasL) and the other expressing Cre recombinase (AxCANCre) (Figure 1a ). AxCALNFasL is a recombinant adenovirus vector, capable of transferring the FasL coding region. The coding sequences are separated from a chicken bactin promoter-cytomegalovirus enhancer (CAG) 34 by a stuffer region which contains a neomycin resistance (Neo r ) gene and is flanked by two Lox-P sequences. In the absence of Cre recombinase, AxCALNFasL expresses only Neo r . Upon infection with AxCANCre, the Lox-Pflanked stuffer region, is removed, permitting the CAG promoter to drive the expression of FasL. The two-virus system was developed because attempts to generate a FasL-expressing adenovirus in 293 resulted in Fasmediated apoptosis of the producer 293 cells.
Experimental design
The bilirubin-UGT-deficient jaundiced Gunn rats were divided into three groups (groups 1-3). Forty-eight hours before transplantation, Gunn Rats were treated with one of the following three regimens: (1) HIR, 50 Gy in a single fraction only, (2) Sham operation followed by injection of AxCALNFasL and AxCANCre and (3) HIR plus injection of AxCALNFasL and AxCANCre.
Hepatocyte transplantation
Forty-eight hours after the preparative treatments of the recipient Gunn rats, HT was performed. The rats were anesthetized with ether and 1 Â 10 7 viable hepatocytes, freshly isolated from donor congenic Wistar-RHA rats, and suspended in 0.5 ml of serum-free Dulbecco's modified Eagle medium, were transplanted by intrasplenic injection. 26 FasL expression, DNA synthesis, and apoptosis of host hepatocytes Two rats in each group were killed 48 h after irradiation and virus injection for determination of FasL expression and hepatocellular apoptosis. Sixty minutes before sacrifice, the animals were injected intraperitoneally with 5-bromo-2-deoxy-uridine (BrdU) (100 mg/kg body weight) for determination of DNA synthesis (see below). The 48 h time point was chosen because this was the time of hepatocye transplantation in the remaining rats in all groups.
FasL expression
The livers were fixed in formalin and paraffin embedded. The paraffin sections were stained using a rabbit polyclonal anti-FasL antibody using an ABC staining kit (Santa Cruz Biotechnology, Inc.).
Hepatocellular apoptosis
The paraffin-embedded sections were also stained using an apoptosis detection kit (ApopTag Plus TM In Situ Apoptosis Detection Kit, Oncor Inc., Gaithersburg, MD, USA) according to the instruction provided by the manufacturer. Briefly, the sections were incubated with terminal deoxynucleotidyl transferase (TdT) in the presence of digoxigenin-labeled nucleotides. Incorporation of the digoxigenin-labeled nucleotides was detected using a peroxidase-conjugated anti-digoxigenin antibody. The slides were developed using a chromogenic substrate for peroxidase.
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Serum bilirubin, AST, and ALT concentrations
Approximately 0.5 ml blood samples were collected from the tail veins of the rats every 7-28 days in all groups. Serum bilirubin, albumin, transferrin, AST, ALT, GGT and alphafetoprotein concentrations were determined using an automated clinical microchemistry system Bayer Chem One (Bayer Corporation, Tarrytown, NY, USA).
Analysis of pigments excreted in bile
At the end of the experiment (150 days after HT), Gunn rats were provided with bile duct cannulae under ether anesthesia and were placed in restraining cages. After the rats gained consciousness and the body temperature returned to normal, bile was collected on ice in a dark room. Bile pigments were analyzed by reverse-phase HPLC using a m-bondapak C18 column (MilliporeWaters, Milford, CA, USA) as described. 35 Peaks were detected by absorbance at 436 nm, identified by retention time using authentic pigment standards, and quantitated by electronic integration of the peak areas.
Immunotransblot analysis for FasL and UGT1A1
After bile collection, rats were killed and their livers were removed for UGT1A1 detection. For detecting FasL content, homogenates were prepared from liver tissues 6, 12, 24 and 48 h after intravenous administration of the AxCALNFasL+AxCANCre adenoviruses. The tissue was minced and 10% homogenates were prepared in 0.25 M sucrose/10 mM Tris/HCl, pH 7.4, 1% Triton X, 10 mM Tris pH 7.4, 150 mM NaCl, 5 mM ethylenediamine tetraacetic acid (EDTA pH 8.0), 1 mM phenylmethylsulfonyl fluoride, 18 ng protein/ml aprotinin, 50 ng/ml leupeptin, using a glass homogenizer fitted with a motorized Teflon pestle. The homogenates (30 mg per lane) were resolved by electrophoresis on a 10% SDS polyacrylamide gels and transferred to a nitrocellulose membrane (Osmonics, MA, USA). FasL was detected using a rabbit polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) to FasL, followed by incubation with an HRP-conjugated goat anti-rabbit IgG (Zymed, CA, USA). Immunotransblot experiments were repeated after absorbing the anti-FasL antibody with a blocking FasL peptide (Santa Cruz Biotechnology). UGT1A1 was detected using a rabbit polyclonal antibody against a rat UGT1A1 peptide and an enhanced chemiluminescence kit (SuperSignal West Dura Extended Duration Substrate, PIERCE, Rockford, IL, USA), followed by exposure to an autoradiography film.
Assay of UGT1A1 activity toward bilirubin
The activity of UGT1A1 was assayed in liver homogenates from experimental Gunn rats and Wistar-RHA rats with bilirubin as the acceptor aglycone substrate, as described. 36 
Identification of engrafted hepatocytes by immunohistochemical staining for rat UGT1A1
At the termination of the experiment, 150 days after HT, sections of paraffin-embedded Gunn rat liver tissues were stained using the rabbit polyclonal anti-rat UGT1A1 antibody. The antibody binding was visualized using an ABC staining kit (Santa Cruz Biotechnology).
